Gilead Sciences, Inc. $GILD Stock: Western Wealth Management LLC Trims Stake

Western Wealth Management LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 54.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 3,650 shares of the biopharmaceutical company’s stock after selling 4,283 shares during the period. Western Wealth Management LLC’s holdings in Gilead Sciences were worth $544,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $15,393,785,000. State Street Corp grew its stake in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares during the period. Amundi raised its holdings in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the completion of the sale, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the sale, the director directly owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 237,709 shares of company stock worth $39,799,137. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 1.0%

Shares of NASDAQ:GILD opened at $167.22 on Thursday. The stock has a market capitalization of $207.41 billion, a price-to-earnings ratio of -52.74 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The stock’s 50-day simple moving average is $156.37 and its two-hundred day simple moving average is $142.23. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the company posted $2.47 EPS. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. HSBC increased their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Morgan Stanley raised their target price on shares of Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Truist Financial lifted their target price on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, Bank of America increased their price target on Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a report on Tuesday, October 20th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.63.

Get Our Latest Report on Gilead Sciences

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Read More

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.